Legal Weight Loss Products Rimonabant for Body-Slimming CAS 168273-06-1

Description

Product name : Rimonabant
Other name :  ACOMPLIA;RIMONABANT;RIMONABANT(ACOMPLIA,SR141716)
CAS : 168273-06-1
MF : C22H21Cl3N4O
MW: 463.79
Assay : 99%
Appearance:White Powder
Usage :  Weight loss powders/ Rimonabant is a selective antagonist
 
Rimonabant is said to have reduced the overall body fat by 10% in one out of three users. Also, it is reported that those users did not gain back more than a kilo over the next two years if the patients remained on Rimonabant. Rimonabant was recommended for those with a BMI of 30 or greater, who were considered obese, and is most successful when combined with exercise and a proper diet. It was not recommended for those who just wanted to lose a few pounds. Rimonabant is valuable in smoking cessation therapy, and initial results are positive.
 
Applications;
 
Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. It was rejected for approval for use in the United States. This decision was made after a U.S. advisory panel recommended the medicine not be approved because it may increase suicidal thinking and depression.
 
Rimonabant works by blocking endogenous cannabinoid from binding to neuronal CB1 receptors. The activation of these receptors by endogenous cannabinoids, such as anadamide, increases an individuals appetite. By blocking the activation of the receptors, appetite suppression may occur.
 
Specification
 

 
Weight Loss Powders series  






Hot-selling products